SAN FRANCISCO--(BUSINESS WIRE)--PellePharm, a late clinical-stage biopharmaceutical company committed to targeting rare dermatologic conditions at their source, today announced that Sanuj K. Ravindran, M.D., chief executive officer and president, will present at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, October 2, at 4:35 p.m. ET in New York.
A live webcast of the presentation can be accessed on the company’s website at www.pellepharm.com. A replay of the webcast will be archived on the PellePharm website for at least two weeks following the presentation.
About PellePharm
Founded by world leaders in hedgehog
pathway signaling, PellePharm is a biotechnology company committed to
targeting rare, genetic dermatological diseases, including Gorlin
Syndrome and High-Frequency Basal Cell Carcinomas (BCCs), at their
source. PellePharm’s mission is to improve the quality of life for those
suffering from Gorlin Syndrome and High-Frequency BCCs by providing an
easy-to-use topical solution that eliminates the need for regular,
painful surgeries. Topical patidegib is a first-in-class topical gel
formulation of a proprietary hedgehog inhibitor.
